MedPath

Assess the Long-term Effectiveness and Safety of Amevive (Alefacept) in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Terminated
Conditions
Chronic Plaque Psoriasis
Interventions
Drug: Amevive exposure
Registration Number
NCT00795353
Lead Sponsor
Astellas Pharma Inc
Brief Summary

The study is a prospective, multi-centre, observational study designed to assess the long-term effectiveness and safety of alefacept in subjects with moderate to severe chronic plaque psoriasis.

Detailed Description

Study includes a bio-marker sub-study to determine differences in responders vs. non-responders. Additional consent is required for the sub-study.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
64
Inclusion Criteria
  • Subjects with moderate to severe chronic plaque psoriasis who receive a new prescription for alefacept
Exclusion Criteria
  • Subjects with a contraindication to alefacept
  • Subjects with a history of cancer except for adequately treated basal cell carcinoma (maximum of 2 lesions)
  • Subjects with any active cancer, including skin cancer
  • Subjects having a serious local infection (eg. cellulitis, abscess) or serious systemic infection (eg. pneumonia, septicemia, tuberculosis), within the 3 months prior to the first dose of alefacept.
  • Subjects known to be infected with the AIDS virus

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
1. Amevive ExposureAmevive exposureCanadian subjects with moderate to severe chronic plaque psoriasis
Primary Outcome Measures
NameTimeMethod
Assess the long-term effectiveness and safety of alefacept in subjects with moderate to severe chronic plaque psoriasis8 Weeks following last dose of each treatment course throughout study
Secondary Outcome Measures
NameTimeMethod
Assess the quality of life of subjects on alefacept based on completion of the Dermatology Life Quality Index8 Weeks following last dose of each treatment course throughout study
© Copyright 2025. All Rights Reserved by MedPath